摘要
目的评价来氟米特联合甲氨蝶呤治疗类风湿性关节炎的临床疗效和安全性。方法选择我院2010年1月至2012年7月治疗的类风湿性关节炎患者92例作为研究对象,遵照知情同意原则并按照随机数字表法分为治疗组和对照组,对照组46例给予甲氨蝶呤治疗,治疗组46例给予来氟米特联合甲氨蝶呤治疗,观察比较两组的临床疗效和安全性。结果治疗组的总有效率为97.8%,明显高于对照组的82.6%,组间差异有统计学意义(P<0.05);治疗组的不良反应发生率为8.7%,对照组为4.3%,两组间差异无统计学意义(P>0.05),两组不良反应症状轻微,均可自行缓解。结论来氟米特联合甲氨蝶呤治疗类风湿性关节炎的临床疗效更佳,并且安全性可靠,是治疗该疾病的首选药物治疗方案之一。
Objective To evaluate the clinical efficacy and safety of leflunomide combined with methotrexate in the treatment of rheumatoid arthritis. Methods 92 patients with rheumatoid arthritis in our hospital from January 2010 to July 2012 were chosen as the research object. In compliance with informed consent principle and in accordance with the random number table, they were divided into treatment group and control group. The control group of 46 patients was treated with methotrexate therapy, and the treatment group of 46 cases was treated with leflunomide and methotrexate. The clinical efficacy and safety of the two groups were compared. Results The total effective rate of the treatment group was 97.8%, significantly higher than 82.6% of the control group, the difference between the groups was statistically significant （P〈0.05）. The incidence of adverse reactions in the treatment group was 8.7%, and 4.3% in the control group, the difference between the two groups was not statistically significant （P〉0.05）. The symptoms of the adverse reactions in the two groups were mild, and could relieve themselves. Conclusions The clinical efficacy of leflunomide in combination with methotrexate in the treatment of rheumatoid arthritis is better, reliable and safe. It is one of the preferred drug programs in the treatment of the disease.
出处
《临床医学工程》
2013年第1期69-70,共2页
Clinical Medicine & Engineering
